Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

3060 Pegasus Park Drive, Dallas, TX, 75247, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

359.4M

52 Wk Range

$4.90 - $35.62

Previous Close

$29.04

Open

$29.17

Volume

118,508

Day Range

$28.23 - $29.55

Enterprise Value

60.95M

Cash

93.41M

Avg Qtr Burn

-14.0M

Insider Ownership

3.97%

Institutional Own.

-

Qtr Updated

09/30/25